Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.2 million.

  • Benitec Biopharma's Free Cash Flow fell 14977.22% to -$8.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$23.6 million, marking a year-over-year decrease of 2166.16%. This contributed to the annual value of -$23.6 million for FY2025, which is 2061.08% down from last year.
  • Per Benitec Biopharma's latest filing, its Free Cash Flow stood at -$8.2 million for Q2 2025, which was down 14977.22% from -$3.1 million recorded in Q1 2025.
  • Benitec Biopharma's Free Cash Flow's 5-year high stood at -$2.0 million during Q1 2021, with a 5-year trough of -$8.2 million in Q2 2025.
  • Over the past 5 years, Benitec Biopharma's median Free Cash Flow value was -$4.4 million (recorded in 2021), while the average stood at -$4.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 16202.86% in 2021, then skyrocketed by 4987.03% in 2025.
  • Benitec Biopharma's Free Cash Flow (Quarter) stood at -$3.3 million in 2021, then plummeted by 76.25% to -$5.9 million in 2022, then grew by 8.76% to -$5.3 million in 2023, then tumbled by 43.93% to -$7.7 million in 2024, then dropped by 6.97% to -$8.2 million in 2025.
  • Its last three reported values are -$8.2 million in Q2 2025, -$3.1 million for Q1 2025, and -$7.7 million during Q4 2024.